تداخلات باميدرونات

Pamidronate disodium is contraindicated in patients with hypersensitivity to pamidronate disodium, other bisphosphonates, or mannitol. (نشرة باميدرونات، موانع الاستعمال)

Pamidronate disodium is contraindicated in patients with hypersensitivity to pamidronate disodium, other bisphosphonates, or mannitol. (نشرة باميدرونات، موانع الاستعمال)

Pamidronate disodium is contraindicated in patients with hypersensitivity to pamidronate disodium, other bisphosphonates, or mannitol. (نشرة باميدرونات، موانع الاستعمال)

Pamidronate disodium is contraindicated in patients with hypersensitivity to pamidronate disodium, other bisphosphonates, or mannitol. (نشرة باميدرونات، موانع الاستعمال)

Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (نشرة باميدرونات، التحذيرات والاحتياطات)

الحديد يرتبط بهذه الأدوية في الأمعاء ويقلّل امتصاصها؛ افصل بين الجرعات. (NIH Office of Dietary Supplements, Iron)

الكالسيوم يرتبط بهذه الأدوية في الأمعاء وقد يقلّص بشدة الكمية الممتصة منها؛ افصل بين الجرعات. (NIH Office of Dietary Supplements, Calcium)

المكملات ومضادات الحموضة المحتوية على المغنيسيوم تقلّل امتصاص هذه الأدوية؛ افصل بين الجرعات بساعتين على الأقل. (NIH Office of Dietary Supplements, Magnesium)

Oxybutynin chloride extended-release tablets should be used with caution in patients who have gastroesophageal reflux and/or who are concurrently taking drugs (such as bisphosphonates) that can cause or exacerbate esophagitis. (نشرة أوكسيبوتينين، التحذيرات والاحتياطات)

Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (نشرة باميدرونات، التحذيرات والاحتياطات)

• Electrolyte disorders (e.g., hypophosphatemia, hypokalemia, hypomagnesemia, hypocalcemia): Monitor phosphorus, potassium, magnesium, calcium and vitamin D and adequately supplement as appropriate. (نشرة باميدرونات، التحذيرات والاحتياطات)

Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (نشرة باميدرونات، التحذيرات والاحتياطات)

Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (نشرة باميدرونات، التحذيرات والاحتياطات)

Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (نشرة باميدرونات، التحذيرات والاحتياطات)

Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (نشرة باميدرونات، التحذيرات والاحتياطات)

Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (نشرة باميدرونات، التحذيرات والاحتياطات)

Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (نشرة باميدرونات، التحذيرات والاحتياطات)

Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (نشرة باميدرونات، التحذيرات والاحتياطات)

• Electrolyte disorders (e.g., hypophosphatemia, hypokalemia, hypomagnesemia, hypocalcemia): Monitor phosphorus, potassium, magnesium, calcium and vitamin D and adequately supplement as appropriate. (نشرة باميدرونات، التحذيرات والاحتياطات)

Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (نشرة باميدرونات، التحذيرات والاحتياطات)

Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (نشرة باميدرونات، التحذيرات والاحتياطات)

The risk of GI hemorrhage may be increased when administering Exjade in combination with drugs that have ulcerogenic or hemorrhagic potential, such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, oral bisphosphonates, or anticoagulants. (نشرة ديفيراسيروكس، التحذيرات والاحتياطات)

Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (نشرة باميدرونات، التحذيرات والاحتياطات)

Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. (نشرة سونيتينيب، التحذيرات والاحتياطات)

Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (نشرة باميدرونات، التحذيرات والاحتياطات)

Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (نشرة باميدرونات، التحذيرات والاحتياطات)

Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (نشرة باميدرونات، التحذيرات والاحتياطات)

Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (نشرة باميدرونات، التحذيرات والاحتياطات)

Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (نشرة باميدرونات، التحذيرات والاحتياطات)

Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (نشرة باميدرونات، التحذيرات والاحتياطات)

• Electrolyte disorders (e.g., hypophosphatemia, hypokalemia, hypomagnesemia, hypocalcemia): Monitor phosphorus, potassium, magnesium, calcium and vitamin D and adequately supplement as appropriate. (نشرة باميدرونات، التحذيرات والاحتياطات)

Closely monitor for signs of renal toxicity when XELODA is used concomitantly with nephrotoxic drugs (e.g. platinum salts, irinotecan, methotrexate, intravenous bisphosphonates). (نشرة كابيسيتابين، التداخلات الدوائية)

• Electrolyte disorders (e.g., hypophosphatemia, hypokalemia, hypomagnesemia, hypocalcemia): Monitor phosphorus, potassium, magnesium, calcium and vitamin D and adequately supplement as appropriate. (نشرة باميدرونات، التحذيرات والاحتياطات)

• Electrolyte disorders (e.g., hypophosphatemia, hypokalemia, hypomagnesemia, hypocalcemia): Monitor phosphorus, potassium, magnesium, calcium and vitamin D and adequately supplement as appropriate. (نشرة باميدرونات، التحذيرات والاحتياطات)

Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (نشرة باميدرونات، التحذيرات والاحتياطات)

Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (نشرة باميدرونات، التحذيرات والاحتياطات)

Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (نشرة باميدرونات، التحذيرات والاحتياطات)

Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (نشرة باميدرونات، التحذيرات والاحتياطات)

Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (نشرة باميدرونات، التحذيرات والاحتياطات)

Concomitant use of bisphosphonates, vitamin D supplementation, and calcium was not allowed. (نشرة إكسيميستان، التحذيرات والاحتياطات)

Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (نشرة باميدرونات، التداخلات الدوائية)

Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (نشرة باميدرونات، التداخلات الدوائية)

Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (نشرة باميدرونات، التداخلات الدوائية)

Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (نشرة باميدرونات، التداخلات الدوائية)

Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (نشرة باميدرونات، التداخلات الدوائية)

Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (نشرة باميدرونات، التداخلات الدوائية)

Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (نشرة باميدرونات، التداخلات الدوائية)

Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (نشرة باميدرونات، التداخلات الدوائية)

Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (نشرة باميدرونات، التداخلات الدوائية)

Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (نشرة باميدرونات، التداخلات الدوائية)

Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (نشرة باميدرونات، التداخلات الدوائية)

Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (نشرة باميدرونات، التداخلات الدوائية)

Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (نشرة باميدرونات، التداخلات الدوائية)

Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (نشرة باميدرونات، التداخلات الدوائية)

Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (نشرة باميدرونات، التداخلات الدوائية)

Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (نشرة باميدرونات، التداخلات الدوائية)

Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (نشرة باميدرونات، التداخلات الدوائية)

Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (نشرة باميدرونات، التداخلات الدوائية)

Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (نشرة باميدرونات، التداخلات الدوائية)

Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (نشرة باميدرونات، التداخلات الدوائية)

Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (نشرة باميدرونات، التداخلات الدوائية)

Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (نشرة باميدرونات، التداخلات الدوائية)

Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (نشرة باميدرونات، التداخلات الدوائية)

Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (نشرة باميدرونات، التداخلات الدوائية)

Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (نشرة باميدرونات، التداخلات الدوائية)

Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (نشرة باميدرونات، التداخلات الدوائية)

Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (نشرة باميدرونات، التداخلات الدوائية)

Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (نشرة باميدرونات، التداخلات الدوائية)

Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (نشرة باميدرونات، التداخلات الدوائية)

Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (نشرة باميدرونات، التداخلات الدوائية)

Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (نشرة باميدرونات، التداخلات الدوائية)